Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro

The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2 and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all inhibitors of coronavirus 3CLpro reported so far are covalent inhibitors. Here, we report the development of specific, noncovalent inhibitors of 3CLpro. The most potent one, WU-04, effectively blocks SARS-CoV-2 replications in human cells with EC50 values in the 10-nM range. WU-04 also inhibits the 3CLpro of SARS-CoV and MERS-CoV with high potency, indicating that it is a pan-inhibitor of coronavirus 3CLpro. WU-04 showed anti-SARS-CoV-2 activity similar to that of PF-07321332 (Nirmatrelvir) in K18-hACE2 mice when the same dose was administered orally. Thus, WU-04 is a promising drug candidate for coronavirus treatment.

[1]  K. To,et al.  Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters , 2022, Science.

[2]  Y. Orba,et al.  Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 , 2022, Journal of medicinal chemistry.

[3]  Malina A. Bakowski,et al.  Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 , 2021, Nature Communications.

[4]  Alice Hooper,et al.  Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro) , 2021, Journal of medicinal chemistry.

[5]  K. Gajiwala,et al.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.

[6]  C. Müller,et al.  3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. , 2021, Journal of medicinal chemistry.

[7]  M. Vignuzzi,et al.  Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 , 2021, Science.

[8]  S. Perlman,et al.  Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection , 2021, Proceedings of the National Academy of Sciences.

[9]  Yuquan Wei,et al.  SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model , 2021, Science.

[10]  Vineet D. Menachery,et al.  Engineering SARS-CoV-2 using a reverse genetic system , 2021, Nature Protocols.

[11]  C. Schiffer,et al.  Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188 , 2021, Viruses.

[12]  Hualan Chen,et al.  Replication, pathogenicity, and transmission of SARS-CoV-2 in minks , 2020, National science review.

[13]  Hamed S. Hayatshahi,et al.  A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors ** , 2020, ChemMedChem.

[14]  E. D. Vita.  10 years into the resurgence of covalent drugs. , 2020, Future medicinal chemistry.

[15]  Chunlong Ma,et al.  Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L , 2020, Science Advances.

[16]  R. Hilgenfeld,et al.  SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging , 2020, Nature Chemical Biology.

[17]  Vineet D. Menachery,et al.  A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 , 2020, Nature Communications.

[18]  J. Chan,et al.  Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters , 2020, Nature Microbiology.

[19]  Catherine Z. Chen,et al.  Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening , 2020, ACS pharmacology & translational science.

[20]  Xiaohong Song,et al.  A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge , 2020, Nature Communications.

[21]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[22]  Z. Bu,et al.  Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice , 2020, Protein & Cell.

[23]  S. Perlman,et al.  3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice , 2020, Science Translational Medicine.

[24]  K. Gajiwala,et al.  Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 , 2020, Journal of medicinal chemistry.

[25]  C. Hallam,et al.  Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice , 2020, Nature Communications.

[26]  D. Waugh,et al.  Faculty Opinions recommendation of Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. , 2020 .

[27]  Jianping Wu,et al.  Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[28]  Hualiang Jiang,et al.  Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease , 2020, Science.

[29]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[30]  L. Guddat,et al.  Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur , 2020, bioRxiv.

[31]  Shinji Makino,et al.  An Infectious cDNA Clone of SARS-CoV-2 , 2020, Cell Host & Microbe.

[32]  Baoying Huang,et al.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.

[33]  A. Mesecar,et al.  Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77 , 2020 .

[34]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.

[35]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[36]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[37]  Christopher J. Williams,et al.  Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix , 2019, Acta crystallographica. Section D, Structural biology.

[38]  Rolf Hilgenfeld,et al.  Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein , 2017, Antiviral Research.

[39]  Yun Ding,et al.  Discovering Drugs with DNA‐Encoded Library Technology: From Concept to Clinic with an Inhibitor of Soluble Epoxide Hydrolase , 2017, Chembiochem : a European journal of chemical biology.

[40]  Anthony D. Keefe,et al.  DNA-encoded chemistry: enabling the deeper sampling of chemical space , 2016, Nature Reviews Drug Discovery.

[41]  Vijay S. Pande,et al.  OpenMM 7: Rapid development of high performance algorithms for molecular dynamics , 2016, bioRxiv.

[42]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[43]  Weizhou Wang,et al.  σ-Hole Bond vs π-Hole Bond: A Comparison Based on Halogen Bond. , 2016, Chemical reviews.

[44]  C. Lindsley,et al.  Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding , 2013, Bioorganic & Medicinal Chemistry Letters.

[45]  C. Lindsley,et al.  Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. , 2013, Journal of medicinal chemistry.

[46]  Paul Labute,et al.  Variability in docking success rates due to dataset preparation , 2012, Journal of Computer-Aided Molecular Design.

[47]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[48]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[49]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[50]  Randy J. Read,et al.  Iterative-build OMIT maps: map improvement by iterative model building and refinement without model bias , 2008, Acta crystallographica. Section D, Biological crystallography.

[51]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[52]  Z. Rao,et al.  Production of Authentic SARS-CoV Mpro with Enhanced Activity: Application as a Novel Tag-cleavage Endopeptidase for Protein Overproduction , 2006, Journal of Molecular Biology.

[53]  K. Yuen,et al.  Correction: Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases , 2005, PLoS Biology.

[54]  J. Hsu,et al.  Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate , 2004, Biochemical and Biophysical Research Communications.

[55]  G. Gao,et al.  The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.